Back

Clinical and economic value of vonoprazan vs. tegoprazan for GERD

Summaries 1 min 87

Font Size

Created On: 27/11/2025

In China’s healthcare system, drug selection is primarily guided by the Pharmacy and Therapeutics Committee (PTC).

See All

Key take away

For GERD management, both vonoprazan and tegoprazan illustrate favorable overall value, with vonoprazan performing marginally better across economic and clinical outcome domains.

Background

In China’s healthcare system, drug selection is primarily guided by the Pharmacy and Therapeutics Committee (PTC). This study utilized the Evidence and Value: Impact on DEcision Making (EVIDEM) framework to assess two newly introduced potassium-competitive acid blockers (P-CABs) — vonoprazan and tegoprazan — to support evidence-based formulary decisions for gastroesophageal reflux disease (GERD) treatment.

Method

Using the 10th edition of the EVIDEM framework, which integrates 5 domains and 13 assessment criteria, 2 independent expert panels were engaged. The PTC expert panel assigned relative weights on a five-point scale, defined scoring indicators, reviewed the evidence matrix, and executed final evaluations. Meanwhile, the evidence matrix expert panel conducted a systematic literature review, developed the evidence matrix, and analyzed the overall value contributions of vonoprazan and tegoprazan.

Result

The total value contribution scores were 0.59 for vonoprazan and 0.54 for tegoprazan. The most prominent differences between the two drugs were observed in the domains of economic impact, comparative clinical outcomes, and therapeutic benefit type.

Conclusion

Vonoprazan illustrated a slightly higher overall value compared to tegoprazan. The findings highlight the practical utility of the EVIDEM framework for structured, transparent, and evidence-based drug evaluation within Chinese healthcare institutions.